Blood Test Shows Accuracy for Diagnosing Alzheimer's Disease
George Washington University
The University of Kentucky’s Sanders-Brown Center on Aging has introduced a groundbreaking initiative, Brain Health Activities, aimed at supporting individuals with dementia and their caregivers.
Researchers at Washington University School of Medicine in St. Louis have developed a way to study aged neurons in the lab without a brain biopsy, allowing them to accurately model the effects of aging in the development of late-onset Alzheimer's disease.
The Cedars-Sinai Accelerator program will greet its 10th accelerator class, featuring 10 innovative health-tech startup companies from the United States and around the globe.
The Alzheimer's Association International Conference (AAIC) 2024 is set to take place from July 28th to August 1st at the Pennsylvania Convention Center in Philadelphia, PA. As the premier event for Alzheimer's and dementia research, AAIC brings together scientists, clinicians, and care professionals from around the world to discuss the latest discoveries and innovations in the field.
A roundup of the latest medical discoveries and faculty news at Cedars-Sinai for July 2024.
Today at ADLM 2024 (formerly the AACC Annual Scientific Meeting & Clinical Lab Expo), researchers will present data on a novel test that predicts whether Alzheimer’s patients are genetically predisposed to side effects from anti-amyloid drugs, a promising new class of Alzheimer’s therapeutics.
Ahora investigadores deACS Central Science demuestran una forma de empaquetar sensores fluorescentes para facilitar su paso a través de la barrera hematoencefálica en ratones, lo que permite mejorar la obtención de imagenología cerebral. Con un mayor desarrollo, la tecnología podría contribuir a avanzar en el diagnóstico y el tratamiento de la enfermedad de Alzheimer.
Now, researchers in ACS Central Science demonstrate a way of packaging fluorescent sensors for easy passage across the blood-brain barrier in mice, allowing for improved brain imaging. With further development, the technology could help advance Alzheimer’s disease diagnosis and treatment.
Cortechs.ai is proud to announce that it has received a 3-year, multimillion dollar NIH grant. Cortechs.ai will use the grant to support the development of additional analysis software to automatically detect and quantify the Amyloid Related Imaging Abnormalities (ARIA) throughout the treatment of Alzheimer's patients to monitor the effects of the therapeutic intervention and to improve patient management.
A head-to-head comparison of six commercially available blood tests for Alzheimer’s disease led by researchers at Washington University School of Medicine in St. Louis reveals that two are accurate enough to replace brain scans and spinal taps in some patients with cognitive impairments.
Our grant proprosal is to identify how two protective mechanisms work and then test them in both European and Amerindian APOE4 genes to see if they work in those genetic backgrounds as well as African.
A research team led by Priya Palta, PhD, MHS, an associate professor of neurology at the UNC School of Medicine, has found that certain Alzheimer’s disease and neurodegenerative blood biomarkers in midlife and late life had strong associations with late-life dementia.
● Roche will unveil the next generation of core lab and molecular systems, including a total solution for clinical mass spectrometry. ● Attendees can experience firsthand how fully integrated systems and data solutions can streamline lab operations, optimize resources and expedite care.
People with high levels of body fat stored in their belly or arms may be more likely to develop diseases like Alzheimer’s and Parkinson’s than people with low levels of fat in these areas, according to a study published in the July 24, 2024, online issue of Neurology®, the medical journal of the American Academy of Neurology.
Investigadores de Mayo Clinic han establecido nuevos criterios para un síndrome de pérdida de memoria en las personas mayores que afecta específicamente al sistema límbico del cerebro. A menudo, este síndrome se puede confundir con la enfermedad de Alzheimer.
UCLA has been selected by the Centers for Medicare & Medicaid Services (CMS) to participate in a new Medicare alternative payment model designed to support people living with dementia and their caregivers.